TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01398072
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An oral dose of 250 mg once daily three times a week (every other day).
Study: NCT01398072
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An oral dose of 100 mg once daily.
Study: NCT03521960
Drug: Buspirone oral capsule
Normalized name: buspirone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 milligrams, three times daily
Study: NCT03521960
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 milligrams (placebo), three times daily
Study: NCT00269737
Drug: Fentanyl Transdermal Therapeutic System (TTS)
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01248494
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose level 1: 400mg PO BID~* Dose level -1: 400mg PO in AM and 200mg PO in PM~* Dose level -2: 200mg PO BID
Study: NCT01248494
Drug: BKM 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose Level 1: BKM120, 100 mg PO daily~* Dose level -1: BKM120, 80 mg PO daily~* Dose Level -2: BKM120, 60 mg PO daily
Study: NCT01248494
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~* Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~* Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly
Study: NCT02289482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
Study: NCT02399592
Drug: Tocotrinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tid
Study: NCT00424333
Drug: Inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00702585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Org 36286 as a single-dose subcutaneous injection
Study: NCT00274872
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00274872
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03878524
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03878524
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03878524
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03878524
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03878524
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03878524
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00885417
Drug: Cravit-based sequential therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
Study: NCT03719482
Drug: [18F]MNI-1054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-1054 injection and PET scan.
Study: NCT01498081
Drug: AZD2115
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2115 administered via inhalation
Study: NCT01498081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via inhalation
Study: NCT04254783
Drug: Cytochrome P450 (CYP) Substrates
Normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
Study: NCT03162497
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 15mg/g eyedrops
Study: NCT03162497
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100 mg per os
Study: NCT00413062
Drug: NOMAC-E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
Study: NCT01669941
Drug: IPTp-SP
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
Study: NCT01669941
Drug: IPTp-DP
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
Study: NCT01669941
Drug: ISTp-DP
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
Study: NCT04624828
Drug: androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT as for clinical practice:~* for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~* for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression
Study: NCT00379262
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
Study: NCT00379262
Drug: Adjuvant chemotherapy using PF (5-Fluorouracil )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
Study: NCT03180489
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
Study: NCT01519284
Drug: BIA 9-1067 5 mg
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 OPC, Opicapone 5 mg
Study: NCT01519284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (four times a day)
Study: NCT01519284
Drug: levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard release levodopa/carbidopa 100/25 mg (single-dose)
Study: NCT01519284
Drug: BIA 9-1067 15 mg
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 OPC, Opicapone 15 mg
Study: NCT01519284
Drug: BIA 9-1067 30 mg
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 OPC, Opicapone 30 mg
Study: NCT03074994
Drug: Peri-articular TXA (15 mg/kg)
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL
Study: NCT02225574
Drug: MEK-162
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle.
Study: NCT00094887
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
Study: NCT00094887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen gas will be delivered in the same manor as the experimental drug.
Study: NCT02486952
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Study: NCT00503542
Drug: Metronidazole or Clindamycin for Bacterial Vaginosis
Normalized name: clindamycin Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
Study: NCT00503542
Drug: Flagyl for definitively diagnosed vaginal trichomoniasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 2 gms po x 1
Study: NCT01333852
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00594204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo 1 tablet twice a day for 12 weeks
Study: NCT00241254
Drug: Cyclophosphamide (drug)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
Study: NCT01825655
Drug: Placebo or sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00835107
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator, oral capsules, BID, for one month
Study: NCT01191905
Drug: Conventional dose CRRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
Study: NCT02006264
Drug: TDF Intravaginal Ring
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
Study: NCT03633565
Drug: Prednisolone (Steroids)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet 20 mg
Study: NCT01606735
Drug: IBI-10090
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone
Study: NCT00413335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receives placebo.
Study: NCT02534909
Drug: LNP023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Period 4: LNP023 200 mg b.i.d. for approximately 20 weeks. Four capsules (each 50 mg) were administered each time study medication was taken.
Study: NCT02024204
Drug: Current Treatment or no treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
Study: NCT03750643
Drug: LY3454738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03750643
Drug: LY3454738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03750643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03253328
Drug: Active Arm N-acetyl cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
Study: NCT03253328
Drug: Placebo Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
Study: NCT02730442
Drug: F901318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of F901318 intravenously
Study: NCT04627142
Drug: Camptosar®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT01454583
Drug: ACE-I/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01454583
Drug: No RAS-inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02638038
Drug: INT131
Approvals — FDA: no, EMA: no, PMDA: no
Description: INT- 131
Study: NCT01413048
Drug: AGSCT101 12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, q.d.
Study: NCT04144855
Drug: TQB3474 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a kind of heat shock protein (HSP90) inhibitor.
Study: NCT01556802
Drug: Minocicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocicline 100mg oral twice a day for 5 days
Study: NCT01556802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills with vegetable fibers one pill oral twice a day for five days
Study: NCT02368249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are receiving a post-operative intravenous Ringer's lactate solution
Study: NCT02566252
Drug: PUL-042 Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUL-042
Study: NCT02221271
Drug: NPB-01
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00118430
Drug: Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
Study: NCT00118430
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
Study: NCT01697267
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%.
Study: NCT03677310
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
Study: NCT02640144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
Study: NCT00557453
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
Study: NCT00557453
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
Study: NCT02123576
Drug: Pentoxyfylline
Normalized name: Pentoxyfylline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02123576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03402152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT02123576
Drug: AMO Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin, midodrine and octreotide therapy (standard of care for HRS)
Study: NCT01864824
Drug: methyl donor
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
Study: NCT01864824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03292952
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose
Study: NCT04762407
Drug: HGP1910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT04762407
Drug: HGP1909
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT04762407
Drug: HCP1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT04032626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04446026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
Study: NCT00084942
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01427283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match OXN or OXY taken orally every 12 hours
Study: NCT04401384
Drug: Diclectin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
Study: NCT05254613
Drug: ALXN1830
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1830 will be administered as SC infusion(s).
Study: NCT05254613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as SC infusion(s).
Study: NCT00671723
Drug: Normal saline:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
Study: NCT00671723
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
Study: NCT01061736
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Same weekly dose as received prior to enrollment
Study: NCT01061736
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to local standard
Study: NCT05904184
Drug: Calcium silicate-based sealers (CSS)
Normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Calcium silicate-based sealers.
Study: NCT02808741
Drug: F901318 SDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics area under curve
Study: NCT02808741
Drug: F901318 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics area under curve
Study: NCT02808741
Drug: F901318 IR Fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics area under curve
Study: NCT01181050
Drug: NNC0142-0002
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
Study: NCT01181050
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).